GlassScriptPhysician profile
Jessica K Eubanks
NPI 1568703684
$2,140.87
in general payments reported to CMS, 2019-2025
28 companies · $328 in 2025
The $328 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $432 · 2022: $225 · 2023: $610 · 2024: $546 · 2025: $328.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,390 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,390.32 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $445.84 | 2021-2025 | |
| Amgen INC. | $227.42 | 2021-2025 | Evenity, Prolia |
| Astrazeneca Pharmaceuticals LP | $207.76 | 2021-2024 | Lokelma, Airsupra, Breztri |
| Lilly USA, LLC | $163.25 | 2021-2025 | Mounjaro, Zepbound |
| Otsuka America Pharmaceutical, INC. | $150.51 | 2023-2025 | Rexulti, Nuedexta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $132.37 | 2021-2023 | Synjardy, Jardiance |
| Astellas Pharma US INC | $94.00 | 2023 | |
| Sumitomo Pharma America, INC. | $88.87 | 2023-2025 | Gemtesa |
| Mylan Specialty L.P. | $79.83 | 2021-2024 | Yupelri |
| Avanir Pharmaceuticals, INC. | $59.21 | 2021-2022 | |
| Lundbeck LLC | $51.54 | 2023-2024 | Rexulti |
| Novo Nordisk INC | $47.71 | 2023-2024 | Ozempic, Rybelsus |
| Dynavax Technologies Corporation | $43.94 | 2023 | Heplisav-B |
| Novartis Pharmaceuticals Corporation | $43.13 | 2023 | |
| Eisai INC. | $37.85 | 2021-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $34.34 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Corium, LLC | $30.54 | 2023 | Adlarity |
| Sunovion Pharmaceuticals INC. | $27.18 | 2021 | |
| Ardelyx, INC. | $26.04 | 2024 | Ibsrela |
| Abbvie INC. | $22.15 | 2021 | |
| Viatris Specialty LLC | $21.30 | 2025 | Yupelri |
| Acadia Pharmaceuticals INC | $17.55 | 2021 | |
| Phathom Pharmaceuticals, INC. | $15.96 | 2024 | Voquezna |
| Glaxosmithkline, LLC. | $15.44 | 2024 | Shingrix |
| Irhythm Technologies, INC. | $14.71 | 2024 | Zio Monitor, Zio Xt Patch |
| Exact Sciences Corporation | $14.58 | 2023 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.14 | 2024 | Xifaxan, Trulance |
| Esperion Therapeutics, INC. | $13.71 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Eubanks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.